Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Osel Sees Immunotherapy-Like Trajectory For Oncology Microbiome Candidate

Executive Summary

Depending on financing, the company could start a Phase III trial of CBM588 as early as this year, but it’s looking to develop the microbiome therapeutic for a potentially broad array of cancers.

You may also be interested in...



Early Success For 4D Pharma’s Microbiome Plus Keytruda Combination

After years of halting progress in its microbiome-based pipeline, 4D Pharma has produced promising early data from its cancer immunotherapy combination.

ViiV’s Cabenuva Could Find Niche In Non-Adherent HIV Patients

The company said results of the LATITUDE trial showed superiority for the long-acting injectable over daily oral pills in patients struggling with adherence to their HIV treatment regimens.

Things Get Worse For Gilead’s Magrolimab

Gilead said the FDA requested a partial clinical hold on the studies as well, just over a week after the drug maker said it would not develop the magrolimab further for blood cancers.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC145998

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel